Maravai LifeSciences Holdings,
MRVI
Positions held
Your positionsMRVI isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Maravai LifeSciences operates in the biotechnology sector, which is experiencing significant growth due to increasing demand for innovative healthcare solutions.
- The company has a market capitalization of approximately $2.91 billion, indicating strong investor interest.
- Analysts recommend a 'buy' with a target mean price of $7.83, suggesting potential upside from current levels.
- Maravai LifeSciences faces challenges with a negative profit margin of -37.07%, indicating ongoing financial struggles.
- Revenue decreased by 22% in the latest quarter compared to the prior quarter, dropping from $66 million to $51 million.
- The operating margin has significantly compressed to -29.4%, reflecting operational inefficiencies.
Fundamentals
| Market cap | $2.67B | Enterprise value | $1.37B | Trailing P/E | — | Forward P/E | -71.63 |
| PEG | — | Price / book | 5.25 | Beta | 0.54 | Dividend yield | 0.00% |
| Revenue growth | 8.5% | Earnings growth | — | Gross margin | 35.7% | Operating margin | -29.4% |
| Profit margin | -37.1% | ROE | -33.0% | ROA | -5.7% | Debt / equity | 0.61 |
| Current ratio | 4.05 | Free cash flow | -$3.62M | Analyst recommendation | buy | Mean target | $7.83 |
| 52w high | $9.42 | 52w low | $2.55 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $51.4M | $65.8M | $49.9M | $41.6M | $47.4M |
| Op margin | -29.4% | 1.1% | -45.2% | -80.7% | -75.6% |
| Net income | -$12.4M | -$3.7M | -$35.7M | -$25.6M | -$39.6M |
| Gross margin | 40.1% | 51.2% | 25.8% | 13.6% | 16.4% |
| Gross profit | $20.6M | $33.7M | $12.8M | $5.7M | $7.8M |
| Operating income | -$15.1M | $0.7M | -$22.5M | -$33.6M | -$35.8M |
- Revenue -22% vs prior quarter ($51M vs $66M).
- Gross margin 40.1% (was 51.2% prior quarter).
- Operating margin compressed to -29.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $186M | $259M | $289M | $883M | — |
| Op margin | -69.2% | -28.0% | -9.9% | 64.1% | — |
| Net income | -$131M | -$145M | -$119M | $220M | — |
| Gross margin | 18.3% | 41.8% | 48.5% | 80.9% | — |
| Gross profit | $34.0M | $108M | $140M | $714M | — |
| Operating income | -$129M | -$72.7M | -$28.5M | $566M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · TD Cowen Initiates Maravai Lifesciences at Buy With $9 Price Target
2026-10-04 · What Is Maravai’s (MRVI) Comeback Really Worth to Investors?
2026-09-25 · Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last?
2026-09-25 · Is Maravai LifeSciences Holdings (MRVI) Cheap If Cash Flow Recovers?
2026-09-24 · Maravai LifeSciences Holdings (MRVI) Rebounded Sharply, Is The Upside Already Priced In?
2026-09-09 · UBS Adjusts Maravai Lifesciences Price Target to $8 From $2.50, Maintains Neutral Rating
2026-08-20 · Sector Update: Healthcare Stocks Fall Late Afternoon
2026-08-20 · Top Midday Gainers
2026-08-14 · Maravai (MRVI) Q2 2026 Earnings Call Transcript
2026-08-07 · Deutsche Bank Adjusts Maravai Lifesciences PT to $8 From $6, Maintains Buy Rating
2026-08-07 · Maravai LifeSciences Holdings, Inc. Q2 2026 Earnings Call Summary
Price (daily)
Full chart · RSI · MACD · patterns